Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Merus N.V. (NASDAQ: MRUS), an oncology company specializing in multispecific antibody therapeutics, has granted stock options to two new employees as inducement awards. The options, approved on August 1, 2025, allow the purchase of up to 240,000 shares at an exercise price of $65.56 per share.

The options have a ten-year term and vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly over three years. These grants were made outside the Company's 2016 Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics^®, Triclonics^® and ADClonics^®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2016 Incentive Award Plan (the “Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 240,000 shares of its common stock to two new employees. The stock options were granted on August 1, 2025. The grant was approved by the Board of Directors and a majority of independent directors based on the recommendation of the Compensation Committee and made as a material inducement to such employees entering into employment with Merus in accordance with Nasdaq Listing Rule 5635(c)(4). The option awards have an exercise price of $ 65.56 per share, the closing price of Merus’ common stock on August 1, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and the standard forms of grant agreements thereunder.

About Merus

Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.

Multiclonics®, ADClonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
Director Investor Relations and Corporate Communications
617-230-4165
k.farren@merus.nl

FAQ

What stock options did Merus (MRUS) grant to new employees in August 2025?

Merus granted options to purchase 240,000 shares to two new employees at an exercise price of $65.56 per share, with a ten-year term and four-year vesting schedule.

What is the vesting schedule for Merus (MRUS) employee stock options granted in August 2025?

The options vest over four years, with 25% vesting on the first employment anniversary and the remaining portion vesting in equal monthly installments over the following three years.

What is Merus N.V.'s (MRUS) main business focus?

Merus is an oncology company that develops innovative full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®).

What was the exercise price for Merus (MRUS) stock options granted on August 1, 2025?

The stock options were granted with an exercise price of $65.56 per share, which was the closing price of Merus' common stock on August 1, 2025.